ProteoNic and Fraunhofer IME sign Research License and start collaboration on protein expression in plants
ProteoNic and Fraunhofer Institute of molecular biology and Applied Ecology (Fraunhofer IME) announced their collaboration regarding protein expression in plant systems. Fraunhofer IME has obtained a Research License to use ProteoNic's UNic(tm) expression technology in a variety of its research projects. In addition, ProteoNic will support Fraunhofer IME by supplying its expertise and research services regarding translation optimization for the development of a plant expression system that produces antibodies at commercially relevant yields.
Stefan Schillberg, Head Department of Plant Biotechnology at the Fraunhofer IME commented: "The IME has pioneered the expression of recombinant antibodies in plants demonstrating that plant cells are capable of expressing antigens and functional antibodies. We believe that implementation of ProteoNic's expression optimization cassettes will allow us to develop improved plant expression vectors finally resulting in increased recombinant protein yields. This will be an important step towards the establishment of sustainable plant production platforms".
ProteoNic CSO Raymond Verhaert remarks: "We are proud that the highly renowned scientists of Fraunhofer IME recognize the value of our expression enhancing technology utilizing the potential of optimizing messenger RNA usage in cell factories. The strong position of Fraunhofer covering the broad range from fundamental research to industrial applications enhances ProteoNic's track record for the UNic(tm) technology and related services for plant expression systems, in addition to our mammalian and fungal applications".
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Balanitis_xerotica_obliterans
Effectiveness of drug to improve natriuretic peptide levels for chronic heart failure

Scientists develop new method to identify glycosylated proteins

Biocatalysis gives access to novel substance classes and elusive species - Novel Manich catalysts and bicyclic carboxylic acid esters synthesised
Premalignant_condition
Iodine_deficiency
